Colfax Corporation’s subsidiary DJO, a maker of devices for musculoskeletal health, joint reconstruction, vascular health, and pain management, has acquired Stryker’s STAR® Ankle and Finger Arthroplasty Systems.  The STAR® system is used to replace an arthritic ankle joint due to osteoarthritis, post-traumatic arthritis or rheumatoid arthritis.  Ankle replacements in the U.S. more than doubled in 2019 as implants have emerged …

Teleflex (NYSE: TFX) has purchased hemostatic device developer Z-Medica from healthcare private equity firm Linden Capital.  The acquisition adds a portfolio of hemorrhage control dressings comprised of gauze impregnated with kaolin, a clay mineral.  Z-Medica’s products address the trauma surgery, EMS, military, emergency department, and interventional segments to complement Teleflex’s vascular access system EZ-IO and blood transfusion kit EZPLAZ with …

Katena Products, producer of ophthalmic instruments, biologics, and lenses and portfolio company of private equity firm Audax Group, is buying St. Clair, MO-based Micro-Select Instruments, a manufacturer of ophthalmic forceps, needle holders, speculums and other instruments.  The acquisition builds on Katena’s November 2019 purchase of St. Louis, MO-based Micro Medical Instruments.  Terms not announced.     Keywords: Healthcare Investment Banking, …

Ireland-based Steris plc, a $3.1b provider of specialty sterilization solutions, equipment processing and endoscope repair services has acquired Key Surgical, a producer of consumables used in minimally-invasive procedures, from private equity firm Water Street.  The acquisition adds OR-focused instruments and other sterile, single-use products that builds on Steris’ leading position in infection prevention and reprocessing technologies.  Deal terms — $850m …

Netherlands-based QIAGEN N.V. (NYSE: QGEN), a $1.5b developer of molecular diagnostic equipment and assays, has acquired a 80.1% ownership stake in diagnostics instruments maker NeuMoDx Molecular, Inc. for $248m.  Qiagen had purchased a 19.9% ownership stake in NeuMoDx in 2018.  The acquisition builds on QIAGEN’s portfolio of automated molecular testing solutions based on PCR technology.  The move also expands QIAGEN’s …

Intersect ENT (Nasdaq: XENT), a $109.1m developer of sinus implants and other ENT-focused products is acquiring Germany-based Fiagon, a developer of proprietary, electromagnetic–based ENT surgical navigation systems for $71.2m.  Fiagon’s instruments, produced in Germany, are tip-tracked, enabling surgeons to monitor the full range of instruments deployed during a functional endoscopic sinus surgery procedure, and they also uniquely do not require …

Bruker Corp. (Nasdaq: BRKR), a $2.1b manufacturer of analytical and diagnostic platforms and instruments is acquiring Canopy Biosciences, a developer of multiplex biomarker imaging technologies for immunology, immuno-oncology and cell therapy to boost Bruker’s CRISPR (clustered regularly interspaced short palindromic repeats) gene editing research capabilities and biopharma drug development business. Canopy Biosciences’ multi-omic (biological analysis) capabilities for immune profiling include …

Koninklijke Philips NV (Royal Philips) (NYSE: PHG), a $19.5b Netherlands-based producer of medical technologies and imaging platforms is acquiring Intact Vascular, Inc., a developer of a minimally invasive implantable device to treat Peripheral Artery Disease (PAD), when narrowed blood vessels restrict blood flow to limbs.  The acquisition strengthens Philips’ market leading peripheral vascular portfolio which includes advanced interventional imaging systems …

Hologic (Nasdaq: HOLX), a $3.4b developer of diagnostics, imaging systems, surgical products, and light-based aesthetic and medical treatment platforms for women is buying Acessa Health, the developer of the Acessa ProVu system, a laparoscopic device combining radiofrequency ablation and advanced intra-abdominal ultrasound to treat benign uterine fibroids (tumors).  The ProVu procedure, addressing fibroids within the uterine wall and on the …

After Thermo Fisher originally announced a $11.5b takeover bid for Netherlands-based Qiagen in March, an amended $12.4b acquisition proposal has since lapsed in accordance with its terms, terminating the deal.    A campaign against the deal spear-headed by institutional investor Davidson Kempner Capital which owned a 3% stake in Qiagen as of March, lead to a shortfall in reaching the minimum …